Indaptus Therapeutics, Inc.

INDP

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001857044


None

No letter

4 of 13 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $9.3M
Warnings	dilution, thin data not computable: degenerate inputs, distress, fortress balance sheet
Inputs computable	4 of 13
Graded from	filings received through Mar 17, 2026 245 days before the rescan; latest periodic filing 10-Q received Nov 13, 2026
Last close	$3.43 2026-11-16; market equity $526.9M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 17, 2026

are a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. We have evolved from more than a century of immunotherapy advances. Our approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Our patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 4.6						
Gross profitability	not computable	32.8%				
one or more required annual facts are missing						

Return on invested capital	not computable	9.6%				
one or more required annual facts are missing						
Accruals ratio	(72.4%)	(6.7%)		4.6	756	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 82.6						
Altman Z double-prime	not computable	0.31				
latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31						
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(3.61x)				
one or more required annual facts are missing						
Current ratio	1.51x	2.68x		82.6	781	2025-12-31
Growth and financing, sleeve percentile 93.1						
Revenue growth, three-year compound	not computable	9.6%				
four annual observations are required; found 0						
Free cash flow growth, three-year compound	not computable	11.1%				
four consecutive annual FCF observations are required; found 1						
Reinvestment rate	not computable	33.9%				
required facts have no common fiscal period end						
Asset growth, three years	(30.8%)	3.2%		93.8	663	2025-12-31
Net share issuance, one year	335.1%	1.6%		92.5	624	2026-03-16

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 335.1%
Thin data	4 of 13 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-16 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(28.6%)	(1.7%)	31
Distance from 52-week high	(27.4%)	(31.5%)	52
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	(2.1%)	0.5%	39
Book value to price	0.02	0.28	13
Sales to price	not computable	0.36	
Composite equity issuance, five years	not computable	13.2%	
Relative strength against the sector, log excess return	(0.51)	(0.19)	31
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$26.6M
Operating cash flow, four quarters	-$13.6M
Months of runway	23.5
Days since last periodic filing	4 (10-Q received Nov 13, 2026)
Median daily dollar volume, 63 sessions	$994,569

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$20.8M	2025-12-31	2026-03-17	10-K	26-010585
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$14.8M	2025-12-31	2026-03-17	10-K	26-010585
3	assets	us-gaap:Assets	$9.3M	2025-12-31	2026-03-17	10-K	26-010585
4	assets	us-gaap:Assets	$7.3M	2024-12-31	2026-03-17	10-K	26-010585
5	current assets	us-gaap:AssetsCurrent	$6.6M	2024-12-31	2026-03-17	10-K	26-010585
6	current liabilities	us-gaap:LiabilitiesCurrent	$3.4M	2024-12-31	2026-03-17	10-K	26-010585
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$60.4M	2024-12-31	2026-03-17	10-K	26-010585
8	operating income	us-gaap:OperatingIncomeLoss	-$15.4M	2024-12-31	2026-03-17	10-K	26-010585
9	book equity	us-gaap:StockholdersEquity	$3.9M	2024-12-31	2026-03-17	10-K	26-010585
10	liabilities	us-gaap:Liabilities	$3.4M	2024-12-31	2025-03-13	10-K	25-010136
11	current assets	us-gaap:AssetsCurrent	$9.3M	2025-12-31	2026-03-17	10-K	26-010585
12	current liabilities	us-gaap:LiabilitiesCurrent	$6.2M	2025-12-31	2026-03-17	10-K	26-010585
13	assets	us-gaap:Assets	$14.9M	2023-12-31	2025-03-13	10-K	25-010136
14	assets	us-gaap:Assets	$28.1M	2022-12-31	2024-03-13	10-K	24-009769
15	shares outstanding	dei:EntityCommonStockSharesOutstanding	2,242,324	2026-03-16	2026-03-17	10-K	26-010585
16	shares outstanding	dei:EntityCommonStockSharesOutstanding	14,429,244	2025-03-12	2025-03-13	10-K	25-010136

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.